GRI Bio
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2223 Avenida De La Playa Ste 208, La Jol...Phone Number
(619) 400-1170Website
www.gribio.comRevenue
-Stock Symbol
GRIIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About GRI Bio
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Explore more
GRI Bio Org Chart
SE
President
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GRI Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when GRI Bio launches new products
Check if GRI Bio has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at GRI Bio
Earning: See what the market has to say on GRI Bio recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once GRI Bio has new funding data
Click to see if GRI Bio had a recent Job posting/layoffs
GRI Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if GRI Bio is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to GRI Bio
Compare insights from companies similar to GRI Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
GRI Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
GRI Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about GRI Bio.
GRI Bio financials insights
Gather financial insights about GRI Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$4.4M
GRI Bio Tech Stack
A closer look at the technologies used by GRI Bio
See more technologies
Most Recent Scoops
Earnings
GRI Bio has reported a net loss of of $3 million for Q1 of fiscal 2025, period ended March 31, 2025.
Earnings, Finance
Earnings
Earnings
Project
Product Management, Intellectual Property, Legal Affairs, Governmental Affairs & Regulation, Pharmaceuticals, Regulations
Project
Product Management, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Earnings
Earnings, Sales, Financial Reporting
GRI Bio News & Media
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that three abstracts and an oral presentation highlighting data from the Phase 2a GRI-0621-IPF-02 study have been selected for presentation at the 2026 European Respiratory Society (ERS) Congress, being held September 5-9, 2026 in Barcelona, Spain.GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivityGRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities when used in combination
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding GRI Bio
Sign Up For FreeTo access detailed company insights
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical... Read More
